Status:
RECRUITING
Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults
Lead Sponsor:
Sheba Medical Center
Conditions:
Dientamoeba Fragilis Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Dientameba Fragilis (D.fragilis) is a protozoan found in the digestive tract - in the human colon. there are disagreements regarding the preferred treatment for these cases, with several regimens test...
Detailed Description
Introduction Dientameba Fragilis (D.fragilis) is a protozoan found in the digestive tract - in the human colon. The route of transmission is fecal-oral, and infection can lead to chronic gastrointesti...
Eligibility Criteria
Inclusion
- Patients over the age of 18, not including pregnant women - With persistent gastrointestinal symptoms (over one month).
- Without any other clear diagnosis to explain these symptoms according to medical records.
- With a positive PCR stool test for D. fragilis without any additional pathogen (patients with Blastocystis hominis in feces will not be excluded).
Exclusion
- Pregnancy
- Hypersensitivity to any of the study drugs or to aminoglycosides
- Patients age below 18 years
- Metronidazole or paromomycin treatment in the last 3 months
Key Trial Info
Start Date :
January 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06907498
Start Date
January 22 2024
End Date
December 1 2026
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba medical center
Ramat Gan, Israel, Israel, 52621